People afflicted with autoimmune diseases may someday receive help through treatments now under development by a Lawrence Livermore National Laboratory licensee and its' collaborations with two major pharmaceutical companies.
LLNL
An analytical technique – known as Droplet™ Digital Polymerase Chain Reaction (ddPCR) – that was developed by LLNL scientists and engineers, has garnered an Impact Award from the Federal Laboratory Consortium. The technology has been commercialized by Bio-Rad Laboratories.
Researchers from Lawrence Livermore National Laboratory (LLNL) and their colleagues who help them commercialize technologies have won three national technology transfer awards this year.
The trio of awards, from the Federal Laboratory Consortium (FLC), represent the most national awards that LLNL has ever won in one year’s competition over the past 36 years.
Two of the awards will be given for technologies to assist in the fight against COVID-19. One employs polymerase chain reaction (PCR) technology to diagnose the SARS-CoV-2 virus (the virus associated with COVID-19) and the other is a mechanical ventilator easily built from readily available parts to assist those suffering from Acute Respiratory